Scarica l'app Stockscreener
103.57
0.29%
0.30
Precedente Chiudi:
$103.27
Aprire:
$103.53
Volume 24 ore:
2.59M
Relative Volume:
1.01
Capitalizzazione di mercato:
$19.77B
Reddito:
$3.08B
Utile/perdita netta:
$-986.58M
Rapporto P/E:
-19.48
EPS:
-5.3172
Flusso di cassa netto:
$292.08M
1 W Prestazione:
+0.07%
1M Prestazione:
+0.32%
6M Prestazione:
+92.01%
1 anno Prestazione:
+140.64%
Intervallo 1D:
$103.45
$103.69
Intervallo di 1 settimana:
$103.22
$103.75
Portata 52W:
$38.81
$103.75
Exact Sciences Corp Stock (EXAS) Company Profile
Nome
Exact Sciences Corp
Settore
Industria
Telefono
608-284-5700
Indirizzo
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS vs TMO, DHR, IDXX, A, WAT
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
103.57 | 19.77B | 3.08B | -986.58M | 292.08M | -5.3172 |
|
TMO
Thermo Fisher Scientific Inc
|
464.37 | 172.51B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
187.32 | 132.46B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
573.82 | 45.69B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.51 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
286.57 | 28.11B | 3.17B | 642.63M | 516.49M | 10.77 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-20 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-01-05 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-03-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-01-02 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-08-02 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-05-05 | Iniziato | UBS | Neutral |
| 2023-03-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-02-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2021-11-03 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Reiterato | BTIG Research | Buy |
| 2021-07-29 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-29 | Reiterato | Oppenheimer | Outperform |
| 2021-07-29 | Reiterato | Stifel | Buy |
| 2021-06-15 | Iniziato | Raymond James | Strong Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Equal Weight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-29 | Downgrade | UBS | Buy → Neutral |
| 2020-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-04-02 | Iniziato | Evercore ISI | Outperform |
| 2020-01-10 | Ripresa | BTIG Research | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Dougherty & Company | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-17 | Reiterato | BofA/Merrill | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-09-26 | Iniziato | Oppenheimer | Outperform |
| 2019-02-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-09-05 | Ripresa | The Benchmark Company | Hold |
| 2018-08-13 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-01-29 | Iniziato | Goldman | Neutral |
| 2018-01-08 | Reiterato | The Benchmark Company | Buy |
| 2017-11-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Downgrade | BTIG Research | Buy → Neutral |
Mostra tutto
Exact Sciences Corp Borsa (EXAS) Ultime notizie
Exact Sciences Corporation $EXAS Shares Purchased by EFG Asset Management Americas Corp. - MarketBeat
Privia Health Screening Program Increases Colorectal Cancer Screening Rates - MyChesCo
Mackenzie Financial Corp Has $150.11 Million Stake in Exact Sciences Corporation $EXAS - MarketBeat
Analysts Set Exact Sciences Corporation (NASDAQ:EXAS) Target Price at $92.13 - National Today
EXACT Sciences Corp. Hits New 52-Week High of $103.75 - Markets Mojo
Schroder Investment Management Boosts Stake in Exact Sciences - National Today
Capital World Investors Reduces Stake in Exact Sciences - National Today
Exact Sciences Case Study Links Higher Screening Rates With Undervalued Shares - Yahoo Finance
Exact Sciences stock hits 52-week high at 103.68 USD - Investing.com India
Exact Sciences EHR Outreach Program Highlights Cologuard Growth And Valuation Debate - simplywall.st
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover - Stocktwits
A Look At Exact Sciences (EXAS) Valuation After Strong 1 Year Shareholder Returns - simplywall.st
CSLLY or EXAS: Which Is the Better Value Stock Right Now? - Yahoo! Finance Canada
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year - BioSpace
EXACT SCIENCES CORP (NASDAQ:EXAS) Shows Strong Technical and Fundamental Momentum - ChartMill
Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration - BioSpace
Exact Sciences Stock: Is The Post-Earnings Slide A Buying Setup for 2026? - AD HOC NEWS
Exact Sciences (NASDAQ: EXAS) EVP exercises 3,900 options, 1,913 shares withheld - Stock Titan
Exact Sciences (EXAS) CEO reports RSU vesting and tax-withheld share dispositions - Stock Titan
KeyCare, Inc. announced that it has received $27.4 million in funding from a group of investors - marketscreener.com
Is Exact Sciences (EXAS) Pricing Reflect Long Term Cancer Screening Growth Potential - Yahoo Finance
Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration – Company AnnouncementFT.com - Financial Times
Exact Sciences Corporation $EXAS Shares Sold by Fox Run Management L.L.C. - MarketBeat
EXAS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pentwater Capital Management LP's Exact Sciences Corp(EXAS) Holding History - GuruFocus
[Form 4] EXACT SCIENCES CORP Insider Trading Activity - Stock Titan
EXACT Sciences (EXAS) HR EVP awarded 23,224 RSUs in new grant - Stock Titan
Exact Sciences (EXAS) grants SVP Herriott 20,321 restricted stock units - Stock Titan
EXACT Sciences (EXAS) CEO receives major RSU grant and tax-share withholding - Stock Titan
Exact Sciences (EXAS) awards 28,063 restricted stock units to EVP Baranick - Stock Titan
Exact Sciences (NASDAQ: EXAS) EVP receives 38,707 restricted stock units - Stock Titan
Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval - Insider Monkey
December 18th Options Now Available For EXACT Sciences (EXAS) - Nasdaq
Market Outlook: Is Exact Sciences Corporation showing insider buyingJuly 2025 Selloffs & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Abbott Labs Increases Dividends for 54 Years, Acquires Exact Sciences - Intellectia AI
Forget Tilray: This Steady Income Stock Beats Wild Cannabis Swings Every Time - The Motley Fool
Abbott offers $20B in notes to finance Exact Sciences acquisition - MassDevice
Abbott Laboratories (ABT) sells $20B of notes to finance Exact Sciences acquisition - Stock Titan
Exact Sciences stock hits 52-week high at $103.55 By Investing.com - Investing.com India
Abbott Laboratories Kicks Off Bond Sale for Exact Sciences Deal - Bloomberg
Abbott lines up one of the year's biggest bond sales at $20B - Crain's Chicago Business
Abbott Laboratories Stock (ABT) Opinions on Exact Sciences Acquisition - Quiver Quantitative
Exact Sciences Stockholders Approve Abbott Merger as Executive Pay Proposal Fails at Special Meeting - Yahoo Finance
Exact Sciences (NASDAQ:EXAS) Hits New 52-Week HighTime to Buy? - MarketBeat
Abbott kicks off bond sale for Exact Sciences deal - Modern Healthcare
Exact Sciences stock hits 52-week high at $103.55 - Investing.com
Abbott Laboratories Commences 8-Part Bond Sale Tied to Exact Sciences Acquisition, Bloomberg Reports - marketscreener.com
Exact Sciences shareholders approve merger with Abbott Laboratories By Investing.com - Investing.com Nigeria
Exact Sciences (EXAS) Shareholders Approve Abbott Acquisition - GuruFocus
Exact Sciences shareholders approve merger with Abbott Laboratories - Investing.com
Exact Sciences stockholders approve acquisition by Abbott - marketscreener.com
Exact Sciences Corp Azioni (EXAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.34%
0.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):